Related Experiment Videos
p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines
J S Skilling1, R C Squatrito, J P Connor
1Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City 52242, USA.
Abstract:
Targeting dysfunctional gene expression in the cancer cell with gene-specific therapeutics requires knowledge of the structure and expression of the designated gene. Because of the prevalence of p53 dysfunction in epithelial ovarian carcinoma, modulation of the expression of this tumor suppressor gene is an attractive target for gene therapy. We sequenced the p53 gene and analyzed its expression in 10 ovarian cancer cell lines. Only five cell line mutations were encountered, three associated with a loss of heterozygosity. Thus, neither p53 mutation nor allelic loss is required for ovarian carcinogenesis or propagation of ovarian cancer cell lines in vitro. SSCP screening, but not immunohistochemical staining, correlated with results of direct genomic sequencing. All p53 immunohistochemical-negative cell lines differed from that reported by another laboratory, underscoring the importance of the knowledge of target gene expression in a given cell line in a given laboratory. We designed pilot studies of antisense oligodeoxynucleotides directed against the p53 gene based on our sequence data. Differential growth inhibition of the A2780-CP-20 cell line (mutant p53 protein), but not of the OVCAR-3 cell line (wild-type p53 protein) confirmed the potential usefulness of this strategy.
Insights
Gene therapy targeting p53 in ovarian cancer is promising. Researchers found that p53 mutations are not always necessary for ovarian cancer development, and antisense therapy showed potential in cell lines.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epithelial ovarian carcinoma frequently exhibits p53 dysfunction.
- Targeting tumor suppressor genes like p53 is a key strategy for gene therapy.
- Understanding p53 gene structure and expression is crucial for developing effective therapeutics.
Purpose of the Study:
- To sequence and analyze p53 gene expression in ovarian cancer cell lines.
- To evaluate the necessity of p53 mutation or allelic loss in ovarian carcinogenesis.
- To assess the feasibility of antisense oligodeoxynucleotide therapy targeting p53.
Main Methods:
- Direct genomic sequencing of the p53 gene.
- Single-strand conformation polymorphism (SSCP) screening.
- Immunohistochemical staining for p53.
- Pilot studies using antisense oligodeoxynucleotides.
Main Results:
- p53 mutations and allelic loss were not consistently found in ovarian cancer cell lines.
- SSCP screening results correlated with direct genomic sequencing.
- Discrepancies in immunohistochemical staining highlight the importance of cell line-specific expression data.
- Antisense oligodeoxynucleotides demonstrated differential growth inhibition in cell lines with mutant vs. wild-type p53.
Conclusions:
- p53 mutation or allelic loss is not essential for ovarian carcinogenesis or in vitro propagation of ovarian cancer cell lines.
- Antisense oligodeoxynucleotide therapy targeting p53 shows potential for ovarian cancer gene therapy.
- Accurate knowledge of target gene expression in specific cell lines is vital for therapeutic design.